
Sign up to save your podcasts
Or


Real Pharma, hosted by Na-Ri Oh and Ian Wendt, with intern Amos Fung
Health technology assessment is usually described as a system. Vidhya Segar describes it as a negotiation between people who are each asking a different question. When she worked in government, the question was always why: why this drug, why now, why this population. In industry, it became why not. In this episode, Na-Ri, Ian, and Amos talk with Vidhya, a pharmacist who has worked as a hospital clinician, as an evaluator at Singapore's national HTA agency, and now in market access at Ipsen. Using Singapore as the working example, the conversation covers how a drug gets from approval to reimbursement, what the US most favored nation (MFN) policy looks like from Southeast Asia, how agencies handle rare disease evidence, and what each side of the table could do to make the other's job easier.
Vidhya Segar is a pharmacist turned national health policy expert turned market access strategist. She began as a hospital pharmacist in Singapore's public health system, working across inpatient and outpatient settings and designing training programs for early career pharmacists. She then moved to the Agency for Care Effectiveness (ACE), Singapore's national health technology assessment body, where she was Senior Assistant Director in the Technology Access Division and led the national rollout of medical device subsidies. Today she is Market Access Manager for Singapore and Malaysia at Ipsen. She is also a regular speaker and moderator at regional pharmacy and health policy conferences and an active voice on LinkedIn on health economics, HTA, and the evolving role of the pharmacist.
[00:00] Intro: The show open and the guest introduction, read in alternating paragraphs by Na-Ri and Ian.
[02:05] Three chairs, one problem: Amos opens with Vidhya's path from acute care pharmacist to national HTA agency to industry. Her version: it was not a grand plan, but sitting on three sides of the access problem changed how she sees it, including the discomfort of realizing that funding one thing means not funding another.
[05:06] There are no bad guys: Why Vidhya thinks most access fights get adversarial, and why people who spend an entire career on one side of the fence tend to lose the ability to see the other side's constraints.
[06:23] A day in the life of a market access manager: What the job actually involves, from dossier submissions to patient access programs to securing tenders, and why the role looks different in a fully reimbursed market than in a partially reimbursed one like Singapore.
[09:30] Why versus why not: The double agent question. What it is like to carry a payer mindset into a business, and why Vidhya thinks the space between "why" and "why not" is where negotiation, and growth, happens.
[10:34] How Singapore's system works: Ian sets the scene with Singapore's reputation for efficient care, then Vidhya walks through the path from regulatory approval to reimbursement: the Health Sciences Authority, the self-pay option inside the government channel, the advisory committees that make the funding decision, and why there is no such thing as 100% reimbursement when everyone is means tested.
[14:04] Real-world evidence and what HTA actually is: ACE's new guidelines on real-world data, why randomized trials remain the gold standard, and Vidhya's argument that people confuse an assessment with a funding decision. Na-Ri adds the US parallel: an FDA approval that cannot find its way onto the market.
[16:25] ACE compared with NICE and ICER: Is ACE stricter than its peers? Vidhya says no, but Singapore's tight link between assessment, funding, and a defined go-live window changes what "access" means in practice.
[18:23] Price, reference baskets, and MFN: How reference pricing works in Singapore, what MFN looks like from Southeast Asia, and Vidhya's concern that industry could overcorrect and underprice drugs for lower-affordability markets. Ian's follow-up: what happens when MFN pressure pushes up the prices Singapore references.
[22:18] Rare disease, cell and gene therapy, and thin evidence: How ACE has approached therapies where robust data is hard to generate, why Vidhya expects case-by-case decisions to continue for the foreseeable future, and what a company can do when reimbursement may not be the answer.
[25:02] Living with uncertainty: Ian asks how a company decides between more randomized trials and a real-world evidence package when the agency's reception is unclear. Vidhya's reframe: both sides want certainty, and certainty is itself a negotiation.
[28:42] What would you change? Vidhya's wish for industry (bring access voices into trial design, because you cannot retrofit evidence) and for agencies (a way to revisit reimbursement decisions as new evidence arrives), plus the resource reality that keeps agencies from doing it.
[32:03] What ACE wished industry understood: Three things: know how the health system you are working in actually funds care, build both a sponsor-friendly and a realistic payer case, and remember it is a long partnership. The elephant hiding behind a pole makes an appearance.
[34:29] Advice for pharmacists thinking about industry: Access work is meaningful even on the industry side, and the best access professionals are corporate polyglots who can speak sales, marketing, medical, and policy. Ian and Na-Ri add their own take on moving from clinical roles into pharma and translating technical work for cross-functional teams.
[38:54] Why she is still in healthcare: Amos closes with the question of what inspires her. Vidhya shares two stories: a clinician's reply to a thank-you email about a rare disease patient group in Singapore, and her grandmother's experience of Parkinson's, which is how she first became curious about drugs.
[42:07] Wrap: Thank yous, and Ian's note that the show is usually very US focused, with some requests to widen the aperture.
On the premise of the whole conversation: "There are no bad guys in this problem. We're all just operating from different constraints with different motivations and different incentives."
On the two questions that frame the negotiation: "When I was in the government, we were always trained to ask why. Why this drug? Why now? Why this population? Why, why, why? On the business side of things, I'm asking, why not?"
On what HTA is and is not: "It is a rigorous assessment. It is a noble assessment, but it is an assessment."
On designing trials with access in mind: "You cannot retrofit evidence."
On keeping the relationship healthy: "Any reimbursement decision that's won with more tension than is required is a Pyrrhic victory, because we're all humans at the end of the day. We remember things."
On communicating across the business: "If you are not accessible to your business partners, you are of no use."
Real Pharma, hosted by Na-Ri Oh and Ian Wendt
As AI moves deeper into drug development, from trial design to evidence generation, the more pressing question isn't what the technology can do. It's who has the authority to decide how it's used. In this episode, Na-Ri and Ian sit down with Donna Cryer, JD, founder of the Global Liver Institute, longtime FDA patient representative, and the person credited with creating the Chief Patient Officer role in Pharma. Donna draws a hard line between patient involvement and patient leadership and makes the case that one changes outcomes while the other is often just theater.
Donna Cryer is a lawyer, patient advocate, and two-time (arguably four-time, counting interim roles) CEO who has spent decades pushing patients from the margins of drug development into governance roles with real authority. She was diagnosed with inflammatory bowel disease at 13, which led to a rare autoimmune liver disease and a liver transplant in her twenties. She founded and led the Global Liver Institute for a decade, serves as an FDA patient representative on advisory committees, sits on the board of PathAI, and built the framework that became the pharmaceutical industry's Chief Patient Officer role.
[00:00] Intro — Framing the episode: patient leadership in a moment when pharma is becoming more data-driven and AI-enabled, and why the real question is one of authority, not just capability.
[02:19] What shaped Donna's philosophy — How a decade building the Global Liver Institute, and a career of being one of the only people in the room who knows where the liver actually is, shaped her approach to patient leadership.
[05:33] Liver disease and stigma — Why most of what people think they know about liver disease is wrong, how stigma shows up differently across hepatitis B, hepatitis C, and cirrhosis, and how Donna worked to change CPT coding so mash patients weren't buried under cardiovascular or diabetes diagnoses.
[07:34] Donna's own story — Diagnosed with IBD at 13, an autoimmune liver disease in her twenties, and a transplant that gave her a kind of authority no amount of professional training can substitute for.
[11:22] Defining patient centricity — Donna's litmus test: did something actually change because a patient was in the room? If nothing changed, it wasn't patient engagement, no matter what the meeting deck says.
[17:47] From involvement to leadership — Why one patient out of twenty on a P&T committee isn't leadership, and what it actually takes for patient input to carry weight in a decision rather than just being collected.
[23:14] Building the Chief Patient Officer role — The origin story, why nearly every CPO hire ended up being a physician despite Donna's original intent, and the trust gap she thinks still needs to close: can a patient leader be trusted with fiduciary and business responsibility, not just advocacy.
[30:09] FDA patient representative: voice vs. vote — What it's actually like sitting on an FDA advisory committee with a vote, not just a comment period, and how that changed the outcome of specific drug approval decisions.
[36:50] Culture and acceptance — The uneven reception patient reps still get in rooms full of physicians and biostatisticians, and Donna's approach to turning skepticism into buy-in, plus her case for clinician training on working with patients as peers rather than problems.
[44:24] AI in pharma — Donna's board role at PathAI, and a guiding principle she credits to a colleague: if a task doesn't require your judgment, your license, or your network, AI can probably do it. Where that leaves the parts of the job that still require a human.
[50:06] Where AI helps, and where it doesn't yet — The problem of patient data missing from the sources most models are trained on, and why patient registries, patient communities, and even patient co-authorship on publications matter for closing that gap.
[51:51] Patient skepticism about AI and health data — Why concerns about data governance and security are real, but patients in genuine medical need are often more willing to adopt AI tools than the industry assumes.
[55:05] Closing advice for pharma CEOs — Donna's ask: don't just bring a patient in to solve "a patient problem." Bring a patient in to help solve the biggest problem facing the company.
On what patient centricity actually requires: "My favorite definition of patient centeredness, and certainly patient engagement, is: did something change because a patient was there? If nothing changed, then it wasn't patient... it certainly wasn't patient engagement."
On the difference a vote makes: "The difference between a voice and a vote. A vote is so much better."
On AI and professional judgment: "If it doesn't need my judgment, my license, or my network, I shouldn't be doing it. AI can probably do it."
Healthcare policies are often evaluated by what they are intended to accomplish. But what happens when the incentives created by those policies produce very different results?
In this episode of RealPharma, Ian Wendt and Dr. Na-Ri Oh speak with longtime health policy expert Deborah Williams about the unintended consequences embedded in the U.S. healthcare system—from hospital reimbursement and industry consolidation to the 340B Drug Pricing Program, biosimilars, most-favored-nation pricing, and pharmaceutical innovation.
Deborah argues that healthcare policy must be judged not by its stated purpose, but by the behaviors, financial incentives, and measurable outcomes it creates. The discussion examines why transparency alone may not lower healthcare costs, how hospital systems use their political and economic influence, and why policies designed to improve affordability can sometimes contribute to higher prices.
The conversation also explores the practical and constitutional uncertainties surrounding most-favored-nation drug pricing, the Trump administration’s GARD, GLOBE, and GENEROUS models, and the potential downstream effects of pricing reform on research, development, manufacturing, and patient access.
Even carefully designed reimbursement systems can produce distortions once stakeholders respond to the incentives. Deborah emphasizes that policymakers must continuously measure what happens after implementation rather than assuming a program is working because its goals are admirable.
Publishing hospital prices may help patients and purchasers compare costs, but transparency has limited value when every available option is still unaffordable. Meaningful reform may also require addressing hospital concentration, market power, and state certificate-of-need restrictions.
Large health systems are often among the biggest employers in a congressional district or state. That employment base, combined with campaign contributions and community influence, makes hospital payment reform politically difficult—even when prices and capital spending appear difficult to justify.
The discussion examines how hospitals may earn substantial spreads between the discounted acquisition cost of a drug and the amount ultimately reimbursed. Those spreads can influence product selection, encourage use of higher-priced brands, and weaken the competitive position of lower-cost biosimilars.
Rather than indirectly subsidizing hospitals through drug-pricing spreads, Deborah suggests that policymakers consider more direct support for uncompensated care, emergency services, obstetrics, psychiatric care, and other socially valuable services.
MFN policies may be politically attractive because Americans pay more for many medicines than patients in other developed countries. However, other countries may be unwilling or unable to increase their spending, leaving manufacturers to absorb much of the financial impact in the United States.
Best-price requirements, 340B discounts, Medicare reimbursement, direct-to-consumer models, and international reference pricing cannot be evaluated in isolation. A change in one area can cascade through the rest of the pharmaceutical pricing system.
Deborah argues that policy analysis should move beyond simply estimating how many drugs might be lost under a pricing reform. The more important question is whether policies reduce the development of first-in-class therapies, novel mechanisms, and clinically meaningful advances.
Episode Summary
What We Cover
Key Takeaways
The episode also highlights a more nuanced view of AI: it is not simply replacing jobs, but it is changing how work gets done. Used well, AI can improve recruiting efficiency, candidate prep, and search precision. Used poorly, it can make candidates sound generic, underprepared, or overly scripted.
What if we’ve been thinking about cancer all wrong?
In this deeply personal and paradigm-shifting episode of RealPharma, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Dr. Christopher Gregg—neuroscientist, entrepreneur, and stage 4 cancer patient—to explore a bold new vision for cancer care.
Dr. Gregg shares how his own diagnosis sparked a radical rethink of oncology: moving away from the “war on cancer” mindset toward managing it as a chronic, controllable condition. Drawing inspiration from agriculture, AI, and evolutionary biology, he introduces the concept of “algorithms as drugs”—dynamic, data-driven treatment strategies designed to outmaneuver resistance.
This conversation blends cutting-edge science with raw human experience, offering a hopeful and pragmatic roadmap for the future of precision medicine.
Why curing cancer may not always be the best goal—and what to aim for instead
The concept of adaptive therapy and managing cancer like a chronic disease
What elephants, farmers, and pests can teach us about treatment resistance
The limitations of today’s drug development and clinical trial systems
“Algorithms as drugs” and the future of programmable medicine
How AI, smartphones, and behavioral data can unlock scalable precision care
The role of value-based care models in accelerating innovation
Dr. Gregg’s personal journey living 7+ years with stage 4 cancer
Building Storyline Health, Primordial AI, and Uncharted Health
The importance of patient agency—and the risks of unguided experimentation
Cancer care is at an inflection point. While billions are spent developing new drugs, Dr. Gregg argues that the real breakthrough may come from how we use the drugs we already have.
By combining AI, real-time patient data, and systems thinking, this approach could dramatically extend lives, reduce costs, and make care more human-centered.
Explore Dr. Gregg’s free masterclass: Uncharted Health
Follow developments from Storyline Health and Primordial AI
Stay tuned for upcoming clinical applications of algorithm-driven care
Dr. Christopher Gregg is a Professor of Neurobiology and Human Genetics at the University of Utah, a leading researcher in genomics and brain science, and a biotech entrepreneur. His work spans neuroscience, AI, and precision medicine—and is deeply informed by his personal experience living with metastatic cancer.
The Opioid Reckoning (Part 2): Litigation, Accountability, and the Fight for Justice with Paul T. Farrell Jr.
In Part 2 of our deep dive into the opioid crisis, hosts Dr. Na-Ri Oh and Ian Wendt continue their conversation with Paul T. Farrell Jr., the West Virginia attorney who helped lead the historic national opioid litigation.
This episode moves beyond the legal strategy discussed in Part 1 and explores the human toll, the documentary that captured the battle, the controversial trial outcome, and the surprising legal reversal years later. It’s a story of perseverance, public health accountability, and the long arc of justice.
Paul shares the unexpected origin story behind the PBS documentary The Bitter Pill, directed by Clay Tweel. What began as a filmmaker casually attending a hearing soon turned into a seven-year chronicle of the opioid litigation, capturing the rise of a local lawsuit in Huntington, West Virginia into a nationwide legal movement.
The documentary highlights not only the legal fight but also the devastating real-world impact of the opioid epidemic on families, healthcare workers, and communities.
A major focus of the episode is the Cabell County trial, the first major test of the legal strategy that ultimately helped drive national settlements.
Paul explains how:
The case became the bellwether trial for thousands of similar lawsuits.
A national settlement framework complicated the ability to settle locally.
The federal judge ultimately ruled against the plaintiffs on legal grounds—even as similar arguments succeeded in other jurisdictions.
For Paul and his team, the ruling felt like a devastating setback after years of work.
Despite the loss in the bellwether trial, the broader litigation resulted in nearly $50 billion in settlements with pharmaceutical manufacturers, distributors, and pharmacies.
Paul explains the goals behind the settlement:
Transparency around how opioid pills were distributed across the U.S.
Accountability for the systemic failures that fueled the epidemic
Funding for opioid abatement programs, rather than compensation for individual claims
In West Virginia, settlement funds were allocated through a unique structure that created the West Virginia First Foundation, a statewide public-private trust designed to ensure funds are used specifically to combat addiction and support recovery programs.
The documentary originally ends on a bleak note after the Cabell County loss. But the story didn’t end there.
In October 2025, the Fourth Circuit Court of Appeals reversed the trial court’s decision, reopening the case and giving Cabell County another opportunity to argue its claims.
For Paul, the decision brought a sense of vindication after years of uncertainty and reignited the fight for accountability.
The episode closes with a broader discussion about whether the opioid crisis could happen again.
Paul reflects on changes across the healthcare ecosystem:
Greater scrutiny and transparency in medical research and publishing
Stronger safeguards for pharmacists and prescription monitoring
Increased attention to controlled substance distribution practices
But he also warns that the incentives in healthcare and pharmaceuticals remain powerful—and vigilance will be essential.
When asked what sustains him through years of litigation, setbacks, and public scrutiny, Paul points to faith, community, and the people who show up along the journey at the right moments.
It’s a fitting close to a story that began with one lawsuit in a small Appalachian city—and grew into one of the largest public health litigations in U.S. history.
The origin and filming of The Bitter Pill documentary
Inside the Cabell County bellwether trial
Why the national opioid settlement unfolded the way it did
The structure and purpose of opioid abatement funding
The 2025 appellate reversal that revived the case
Whether the healthcare system has truly changed
Paul T. Farrell Jr.
The Opioid Reckoning (Part 1): Paul Farrell Jr. on Litigation, Accountability, and the System That Failed
West Virginia has had the highest drug overdose death rate in the United States for over a decade. In a state with fewer than 2 million people, 780 million prescription opioids were distributed in just six years.
For Paul Farrell Jr., a Huntington, West Virginia native and mass tort attorney, those numbers weren’t abstract statistics. They were neighbors. Friends. Family members.
In Part 1 of this two-part episode, hosts Na-Ri Oh and Ian Wendt sit down with Paul to unpack how the largest civil litigation in American history — the opioid multidistrict litigation (MDL 2804) — came together, and how it reshaped the conversation around corporate accountability in the pharmaceutical supply chain.
This is not just a legal story. It’s a story about systems failure — across manufacturers, distributors, regulators, policymakers, and healthcare stakeholders — and what happens when transparency finally forces a reckoning.
Growing up in Huntington, WV as the opioid crisis escalated
The investigative journalism that exposed 780 million pills — and the moment Paul decided to act
What “public nuisance” law is — and why it became the legal breakthrough strategy
The role of distributors as the “choke point” in the opioid supply chain
How 3,000+ cases consolidated into the largest MDL in U.S. history
Why abatement — not just financial damages — became central to the settlement strategy
Internal company communications that revealed troubling attitudes toward affected communities
The intersection of regulation, enforcement, and corporate responsibility
How transparency and subpoena power changed the trajectory of the crisis
For those working in pharma, healthcare, commercialization, policy, compliance, or distribution, this episode challenges us to examine difficult questions:
Where does responsibility truly lie in a complex healthcare ecosystem?
What happens when financial incentives distort oversight?
And how do we prevent the next Pandora’s box from opening?
This episode sets the foundation for a deeper conversation about accountability, culture, regulation, and reform.
There was simply too much to cover in one episode.
In Part 2, we’ll explore:
The evolution of the litigation and key tipping points
The role of state attorneys general and settlement frameworks
The ongoing PBM litigation
The documentary The Bitter Pill
And what lasting change should look like for the industry
Make sure to subscribe so you don’t miss it.
Hosts: Na-Ri Oh & Ian Wendt
What if the biggest innovation in rare disease wasn’t a new drug—but a new way to navigate the system?
In this episode, Na-Ri and Ian sit down with Joshua Resnikoff, biomedical engineer turned founder of Sunstone Health, to explore how employers can fundamentally rethink healthcare spending—while dramatically improving outcomes for families facing rare diseases.
Josh’s journey into healthcare reform wasn’t academic—it was personal. After years navigating the healthcare system to diagnose his son’s rare periodic fever syndrome, Josh experienced firsthand the emotional, financial, and systemic toll of what’s known as the diagnostic odyssey. That experience sparked a mission: compress a seven-year diagnostic journey into just 12 weeks.
This conversation dives into rare disease, employer-sponsored health plans, insurance mechanics, and why aligning incentives might be the key to transforming care.
Josh’s background as a biomedical engineer at Harvard’s Wyss Institute
The rare disease journey that reshaped his career
Why getting a diagnosis—even without treatment—changes everything
The emotional and economic cost of delayed diagnosis
On average, it takes:
7 years from first symptom to effective treatment for rare disease patients
Countless ER visits, specialist referrals, medication trials, and escalating costs
Significant emotional strain—rare disease families face dramatically higher stress and divorce rates
Sunstone’s model reduces that timeline to approximately 12 weeks using:
Whole genome sequencing
AI-powered clinical interpretation
Expert clinician review (human-in-the-loop model)
Direct coordination with local care teams
The result?
Josh explains why self-funded employers—not traditional commercial insurers—are uniquely positioned to drive change.
Key insights:
~2/3 of Americans receive insurance through employers
Many large employers are self-funded, meaning they pay claims directly
Employers think in long-term employee retention (not 12-month insurance cycles)
Better healthcare = healthier employees = higher retention & productivity
Sunstone’s innovative model:
No per-employee-per-month subscription fees
Employers only pay when a family receives actionable results
High ROI through reduced ER visits, unnecessary treatments, and delayed care
The episode breaks down:
Fully insured vs. self-funded plans
Third-party administrators (TPAs)
Stop-loss / reinsurance
How high-cost cases (like $2M gene therapies) are financially managed
The takeaway:
A powerful theme throughout the conversation:
Many leaders in the rare disease ecosystem—including Josh—entered the field because of their own children.
That lived experience shapes:
Sunstone’s patient-first data ownership model
Continuous reanalysis of patient data
Clinical trial matching
Ethical alignment with families
As Josh says:
“Even if this whole thing went belly up, we will have helped hundreds of families—and I’d feel good about that for the rest of my life.”
Successfully raised Series A funding
800+ community investors via WeFunder
Integration with Broad Clinical Labs
Expanded epilepsy and autism-focused programs
Rapidly growing employer pipeline
🌐 Sunstone Health: https://sunstonehealth.com
💼 Connect with Josh on LinkedIn
Episode Summary:
In this no-holds-barred conversation, Na-Ri Oh and Ian Wendt sit down with Matthew Zachary—brain cancer survivor, founder of Stupid Cancer, host of Out of Patients, and a relentless disruptor in patient advocacy.
At 21, Matthew was diagnosed with brain cancer and faced a life-altering decision: take chemotherapy and lose his identity as a musician, or reject treatment and risk everything. That decision became the first of many moments where he saw the cracks in the healthcare system—specifically, the glaring absence of empathy.
Now, nearly three decades later, Matthew shares how his experience transformed into a mission to fix what’s broken: in pharma, in media, in patient engagement—and in how we talk about what matters most.
This isn’t your typical Pharma Podcast. It’s a masterclass in calling out BS, rethinking metrics that matter, and re-centering real human lives in healthcare strategy.
What You’ll Hear in This Episode:
🎹 The life-defining decision Matthew made at 21—and why he turned down chemo
💊 How a lack of empathy almost cost him everything
🧠 The problem with patient engagement that’s all talk and no trust
🎤 The rise of Stupid Cancer and the “Howard Stern of Healthcare” era
📺 Why DTC ads may be a $28 billion distraction
🧵 The missing link between pharma marketers and patient communities
🔥 How compliance is killing creativity—and what to do about it
🗳️ Why Matthew is building a voter movement out of patient voices
Memorable Quote:
“If there is no empathy, there is no conversation.” – Matthew Zachary
Mentioned in the Episode:
Stupid Cancer
Out of Patients Podcast
Matthew’s upcoming book: We the Patients: How to Understand, Navigate, and Survive America’s Healthcare Nightmare
WeThePatients.org
Guest:
Matthew Zachary (@MatthewZachary)
Let me know if you'd like a shorter version for Spotify/Apple Podcast platforms or suggested social media captions to promote the episode.
From the publisher's feed

39,189 Listeners

26,216 Listeners

4,458 Listeners

134 Listeners

112,266 Listeners

1,426 Listeners

9,069 Listeners

348 Listeners

249 Listeners

6,069 Listeners

10,173 Listeners

33 Listeners

780 Listeners

57,804 Listeners

5,583 Listeners